Bendamustine, followed by obinutuzumab, acalabrutinib and venetoclax in patients (Pts) with relapsed/refractory chronic lymphocytic Leukemia (CLL): updated results of the CLL2-BAAG trial of the German CLL Study Group (GCLLSG)-MedSci.cn

Bendamustine, followed by obinutuzumab, acalabrutinib and venetoclax in patients (Pts) with relapsed/refractory chronic lymphocytic Leukemia (CLL): updated results of the CLL2-BAAG trial of the German CLL Study Group (GCLLSG)

Cramer, P; Fürstenau, M; Robrecht, S; Giza, A; Fink, A; Fischer, K; Langerbeins, P; Al-Sawaf, O; Tausch, E; Schneider, C; Schetelig, J; Dreger, P; Böttcher, S; Kreuzer, KA; Schilhabel, A; Brüggemann, M; Kneba, M; Wendtner, C; Stilgenbauer, S; Eichhorst, B; Hallek, M

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Bendamustine, followed by obinutuzumab, acalabrutinib and venetoclax in patients (Pts) with relapsed/refractory chronic lymphocytic Leukemia (CLL): updated results of the CLL2-BAAG trial of the German CLL Study Group (GCLLSG)

科室

工具

服务